Clinical trials: Triple Negative Breast Cancer (TNBC)
Advanced Melanoma, Triple-Negative Breast Cancer
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or metastatic TNBC Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination…
- Trial name
- NCT02981303
- Testing
- Imprime PGG, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- HiberCell, Inc.
Triple Negative Breast Cancer
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
The combination of chemotherapy with PD-1 immune checkpoint blockade agents demonstrated promising results especially in the neo-adjuvant and early metastatic setting in TNBC.
- Trial name
- SYNERGY (NCT03616886)
- Testing
- Paclitaxel, Carboplatin, MEDI4736
- Where
- 16 sites in Belgium, France
- Volunteers
- 129 people
- Sponsor
- Jules Bordet Institute
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Triple-Negative Breast Cancer (TNBC)
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with…
- Trial name
- NCT07729956
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer
Axillary Nodal Burden in HER2+ and TNBC
This study aimed to evaluated rates of pathologic axillary nodal metastasis in patients with with early-stage HER2-positive BC or TNBC who had clinically node-negative status on preoperative ultrasonography and underwent upfront…
- Trial name
- NCT07211451
- Testing
- Breast conserving surgery with axillary surgery
- Where
- South Korea
- Volunteers
- 1,571 people
- Sponsor
- Gangnam Severance Hospital
TNBC, Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined…
- Trial name
- NCT06682195
- Testing
- Neoadjuvant chemotherapy combined with Toripalimab
- Where
- 13 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non-Metastatic Breast Carcinoma
Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy
Background: Triple negative breast cancer (TNBC) is characterized by an aggressive biological behaviour responsible for higher risk of recurrence and shorter median survival.
- Trial name
- PEMCLOCK (NCT06418139)
- Testing
- No intervention
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BRCA1 Mutation, High-grade Serous Ovarian Cancer
Breast Cancer BRCA1 Carriers: a Pilot Study
The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates…
- Conditions
- BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05062174
- Testing
- Mifepristone 200 MG, Prophylactic mastectomy
- Where
- 2 sites in United States
- Sponsor
- Indiana University
Triple Negative Breast Cancer
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2.
- Trial name
- TNBC (NCT03901469)
- Testing
- ZEN003694, Talazoparib
- Where
- 19 sites in United States, Belgium and 2 more
- Volunteers
- 115 people
- Sponsor
- Zenith Epigenetics
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression.
- Trial name
- NCT02659631
- Testing
- PF-06671008
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
- Trial name
- DB-08 (NCT04556773)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Breast Cancer
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR positive breast cancer.
- Trial name
- NCT02833766
- Testing
- anti-EGFR-IL-dox
- Where
- 15 sites in Switzerland
- Volunteers
- 48 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with…
- Trial name
- NCT07487519
- Testing
- HLX43 DOSE 1 IN ≥2L TNBC, HLX43 DOSE 2 IN ≥2L TNBC, HLX43 DOSE 1 + HLX10
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Breast Carcinoma
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal.
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Trial name
- NCT07619534
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Triple Negative Breast Cancer
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
This phase II randomized trial is for patients with clinical stage II-III, ER and PR <10%, HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT is planned and pre-operative RT is deemed…
- Trial name
- PANDoRA (NCT03872505)
- Testing
- Durvalumab, Radiation Therapy, Carboplatin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Triple Negative Breast Cancer
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for…
- Trial name
- NCT04427293
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois at Chicago
TNBC - Triple-Negative Breast Cancer, TNBC
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
This is a single-arm and single site phase II trial combination of chemotherapy and pembrolizumab with LBP MO-03 in 50 trial participants with early triple negative breast cancer.
- Conditions
- TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07552181
- Testing
- Live biotherapeutic product: MO-03 1 capsule PO BID
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Yuan Yuan
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Breast Cancer, Triple Negative Breast Cancer (TNBC)
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC
This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the BLIS subtype.
- Trial name
- TRIBE (NCT07669610)
- Testing
- SHR- A1811, SHR-A1811+BEV
- Volunteers
- 140 people
- Sponsor
- Fudan University